Also trades as: 0JDK.L (LSE) · $vol 3M
IOVA NASDAQ
Iovance Biotherapeutics, Inc.
1W: -1.9%
1M: +32.7%
3M: +219.7%
YTD: +478.6%
1Y: +548.0%
3Y: +337.8%
5Y: -44.4%
$14.58
+0.80 (+5.81%)
Weekly Expected Move ±18.3%
$9
$12
$14
$17
$19
Credit Risk of going bust: lower than 52% of companies Debt: 0.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.9%), Iovance Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $46.0M against a stock market value of $6.60B.
Distance to default 5.33 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $23.0M (short-term plus half of long-term), stock volatility 98.4%; Altman Z'' -5.65. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.9%), Iovance Biotherapeutics, Inc. would be worth roughly what it owes.
Total debt $46.0M against a stock market value of $6.60B.
Distance to default 5.33 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $23.0M (short-term plus half of long-term), stock volatility 98.4%; Altman Z'' -5.65. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
9 relationships8
As Filer
counterparties named
1
As Counterparty
mentioned by others
3
Rel. Types
2023-05-18
Earliest Filing
2025-08-22
Latest Filing
target: 4
partner: 2
supplier: 2
Counterparties (Filed by IOVA)
8 relationshipsCompanies named in IOVA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Jefferies LLC | JEF | partner | Sales agent for an at-the-market offering of up to $350 million of common stock. | 2025-08-22 | View |
| Vaxcyte, Inc. | PCVX | supplier | Counterparty to the New Headquarters Lease agreement for office space. | 2024-11-21 | View |
| ARE – San Francisco No. 63, LLC | — | supplier | Landlord providing consent for the New Headquarters Lease. | 2024-11-21 | View |
| Jefferies LLC | JEF | partner | Sales agent for at-the-market offering of common stock | 2023-06-16 | View |
| Clinigen Holdings Limited | — | target | Seller of worldwide rights in Proleukin (aldesleukin) and target of asset acquisition | 2023-05-18 | View |
| Clinigen Healthcare Limited | — | target | Seller of worldwide rights in Proleukin (aldesleukin) and target of asset acquisition | 2023-05-18 | View |
| Clinigen, Inc. | — | target | Seller of worldwide rights in Proleukin (aldesleukin) and target of asset acquisition | 2023-05-18 | View |
| Clinigen SP Limited | — | target | Wholly owned subsidiary of Clinigen acquired by Iovance Biotherapeutics | 2023-05-18 | View |
Mentioned As Counterparty
1 mentionsOther companies that named IOVA in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-05 | Other Events; Exhibits | View | |
| 2026-09-29 | Other Events; Exhibits | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-08-06 | Other Events; Exhibits | View | |
| 2026-07-02 | Other Events; Exhibits | View | |
| 2026-06-10 | Shareholder Vote; Other Events; Exhibits | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-03-20 | Officer/Director Change | View | |
| 2026-02-24 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2026-01-09 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-29 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-22 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-08-19 | Other Events; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-07-15 | Departure/Election of Directors; Appointment of Officers; Other Events; Financial Statements and Exh | View | |
| 2025-07-03 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-06-13 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-06-10 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR